Thus, FAS inhibition reduces the level of HER2 expression and significantly increases the sensitivity of cancer cells to HER2 inhibition [105] Similarly, inhibition of CPT1 re-sensitizes chronic lymphocytic leukemia cells resistant to the tyrosine kinase inhibitor, ibrutinib [97] and inhibition of SCD1 reverts resistance to cisplatin in lung cancer stem cells [96]. Here, ERBB2 is linked to lung cancer.